CNIM
CNIM - in partnership with Socarenam , Mauric and CNN MCO - has been awarded the contract to replace the French Navy's landing crafts. Fourteen new Standard Amphibious Landing Crafts (EDA-S) are to be built over a ten-year period. This contract reasserts CNIM's status as a key partner to the French Navy and a European leader in the area of amphibious operations, supplying the complementary innovative vessels: EDA-S and EDA-R (already in service in the French Navy, designed by CNIM).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190121005420/en/
Next-generation of vessels designed by CNIM
"Winning this European tender reasserts CNIM's status as experts in amphibious craft design. CNIM is to replace the French Navy's existing landing craft with fourteen new Standard Amphibious Landing Craft, also called EDA-S", notes Philippe Demigné, a CNIM Board Member.
These vessels will conduct amphibious operations from the well decks aboard Mistral-class amphibious assault ships (referred to “force projection and command ships”), carrying troops, military equipment or vehicles. They will be able to take part in logistics operations, depending on their location. They are also designed to evacuate citizens and recover air-dropped equipment during humanitarian missions.
Eight EDA-S craft will be assigned to the amphibious flotilla (FLOPHIB) based in Toulon, replacing the existing equipment transport barges (CTM). The EDA-S and EDA-R* landing craft will be carried aboard BPC amphibious assault ships.
The other six EDA-S will be deployed overseas, replacing various logistics barges**.
*EDA-R: Fast Amphibious Landing Craft, also designed by CNIM. Four EDA-R have been in service with the French Navy since 2011.
** based in Djibouti (2), Mayotte (1), Nouméa (1), Fort-de-France (1) and Kourou (1).
Strong fit between the EDA-S and EDA-R amphibious craft
The EDA-S and EDA-R are complementary in terms of mission capabilities and speed; they have similar load capacities*** and are both able to conduct amphibious operations in very shallow water (<1m deep).
Aboard a force projection and command ship, the French Navy can sail with either four EDA-S or two EDA-S and an EDA-R, as required.
*** The EDA-S is designed to carry 65 tonnes in its nominal load configuration, and has a maximum load of 80 tonnes, equivalent to the nominal load of the EDA-R.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190121005420/en/
Contact:
PR agency Frédérique Vigezzi frederique.vigezzi@gootenberg.fr Tel.: + 33 1 43 59 29 84 CNIM Nathalie Sablon nathalie.sablon@cnim.com Tel.: +33 1 39 30 62 11
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Registrar Corp Acquires CMC Medical Devices to Make Global Compliance Quick and Easy5.11.2025 13:00:00 CET | Press release
Expands Registrar Corp’s reach to support over 75% of the global medical device market. Registrar Corp, a global leader in regulatory compliance and technology solutions and a Paine Schwartz Partners portfolio company, today announced the acquisition of CMC Medical Devices (CMC), a Spain-based provider of medical device regulatory, clinical, and compliance consulting services. The combination of Registrar Corp’s global network and CMC’s clinical and technical expertise creates a unified partner to help medical device and in vitro diagnostic (IVD) manufacturers bring products to market faster and with greater confidence. “We’re proud to welcome CMC Medical Devices to the Registrar Corp family,” said Raj Shah, CEO of Registrar Corp. “Together, we offer medical device manufacturers a single partner to navigate complex regulations and access the U.S., EU, and other key global markets—so they can focus on innovation rather than compliance.” “Joining Registrar Corp enables us to deliver even
Cybersecurity Leader Armis Closes $435 Million Round at $6.1 Billion Valuation5.11.2025 13:00:00 CET | Press release
In a pre-IPO round led by Growth Equity at Goldman Sachs Alternatives and with significant participation from CapitalG, Armis accelerates on the path to $1 billion in ARR and a public offering Armis, the cyber exposure management and security company, today announced a pre-IPO funding round of $435 million, bringing the company’s valuation to $6.1 billion. The round was led by Growth Equity at Goldman Sachs Alternatives with major participation from CapitalG, and was joined by new investor Evolution Equity Partners, alongside several existing investors. The investment round comes amid continued growth, with the company recently surpassing $300 million in Annual Recurring Revenue (ARR), growing over 50%. Armis has worked with over 40% of the Fortune 100, including 7 of the Fortune 10, and helps protect leading organizations around the globe, including manufacturers, airlines, financial services firms, healthcare institutions, and state and federal agencies. Yevgeny Dibrov, CEO and Co-Fo
Macrobond Selected by T. Rowe Price to Support Evolving Research and Investment Workflows5.11.2025 13:00:00 CET | Press release
Macrobond, the global platform for macroeconomic and financial data, has been selected by T. Rowe Price to support the continued evolution of its cross-asset research and systematic strategy workflows. As financial institutions look to strengthen data-driven decision-making, the need for scalable technology and integrated platforms has never been more critical. T. Rowe Price’s decision to implement Macrobond reflects a broader commitment to enhancing research workflows with modern, flexible solutions built for the pace and complexity of today’s investment landscape. Meeting the Demands of a Dynamic Environment The ability to integrate complex data sets, streamline analysis, and support automation were key factors in the selection process. Macrobond’s API and flexible data infrastructure provided a strong foundation for collaboration. “T. Rowe Price is continually investing in technology to improve the efficiency and quality of our research processes,” said Tae Kim, Head of Fixed Income
Compass Pathways to Participate in Stifel 2025 Healthcare Conference5.11.2025 12:30:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the Stifel 2025 Healthcare Conference in New York, NY at 10:40 am ET on Tuesday, November 11, 2025. A live audio webcast of these events will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational COMP36
Watchmaker Genomics Launches TAPS+, Expanding Multimodal Capabilities in Oncology Ahead of AMP 20255.11.2025 12:00:00 CET | Press release
- TAPS+ enables simultaneous detection of methylation and genetic variants, unlocking new insights for precision oncology and translational research. - Preserves DNA integrity in challenging clinically relevant samples, including FFPE tissue and circulating tumor DNA (ctDNA). - Platform-agnostic chemistry enables seamless integration across sequencing systems. Watchmaker Genomics today announced the launch of TAPS+, a next-generation technology that unites genetic and epigenetic readouts from the same DNA molecule. By capturing multiple biological dimensions in a single assay, TAPS+ delivers a richer, more comprehensive view of tumor biology, with the power to advance applications in translational oncology, early cancer detection, therapy response monitoring, fragmentomics, and minimal residual disease assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105264633/en/ Watchmaker Genomics launches TAPS+, a next-gener
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
